AMGN vs JANX · P/E 24, rev $10.05B vs rev $10.3M
Amgen Inc (AMGN) versus Janux Therapeutics Inc (JANX) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Janux Therapeutics Inc (JANX) is a biotechnology company listed on US.
Latest reported AMGN revenue for 2026-06-30 was $10.05B. Net income was $2.38B. Revenue was up 16.7% from 2026-03-31 to 2026-06-30. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported JANX revenue for 2026-06-30 was $10.3M. Net income was -$22.0M. JANX currently screens at market cap $1.49B.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. JANX currently screens at market cap $1.49B.
Not investment advice. Open the AMGN and JANX stock pages for the full models.
Not investment advice.